GIPC Activators
The chemical class of GIPC activators encompasses a diverse array of compounds that influence GIPC expression and function through various mechanisms, shedding light on the intricate regulation of this signaling protein. GIPC, or GAIP-interacting protein, plays a crucial role in mediating cellular responses to various extracellular signals, including growth factors, hormones, and cellular stress. Brefeldin A, a GBF1 inhibitor, indirectly activates GIPC by disrupting vesicular trafficking, enhancing GIPC interaction with target proteins. This reveals the connection between vesicle dynamics and GIPC function, offering a chemical tool to explore GIPC-related pathways in the context of altered intracellular trafficking. Clostridium difficile Toxin B, a Rho GTPase activator, indirectly activates GIPC by influencing GIPC-mediated signaling pathways through Rho GTPase activation. This reveals the interplay between Rho GTPase dynamics and GIPC function, offering a chemical tool to explore and modulate GIPC-related pathways in the context of altered Rho GTPase activity.
Raloxifene, a selective estrogen receptor modulator, indirectly activates GIPC by interacting with estrogen receptors, influencing GIPC expression and function in estrogen-responsive tissues. This highlights the hormonal regulation of GIPC, providing a pharmacological tool to explore GIPC-related pathways in the context of hormonal signaling and potential implications in estrogen receptor-mediated cellular processes. DAPT, a gamma-secretase inhibitor, indirectly activates GIPC by inhibiting Notch signaling, influencing GIPC-mediated cellular processes. This sheds light on the cross-talk between Notch signaling and GIPC function, providing a pharmacological tool to explore GIPC-related pathways in the context of altered Notch signaling dynamics. TPA (12-O-Tetradecanoylphorbol-13-acetate), a PKC activator, indirectly activates GIPC by activating PKC, influencing GIPC-mediated signaling and cellular functions. This reveals the role of PKC in regulating GIPC function, providing a pharmacological tool to explore GIPC-related pathways in the context of altered PKC signaling dynamics.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin, an adenylyl cyclase activator, indirectly activates GIPC. By elevating cAMP levels, it activates PKA, leading to GIPC phosphorylation and enhanced GIPC-mediated signaling. Forskolin's indirect activation of GIPC highlights the role of cAMP-PKA signaling in modulating GIPC function, providing a pharmacological tool to investigate GIPC-related pathways in cellular contexts. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A, a GBF1 inhibitor, indirectly activates GIPC. By disrupting vesicular trafficking, it enhances GIPC interaction with target proteins, influencing GIPC-mediated cellular processes. Brefeldin A's indirect activation of GIPC reveals the connection between vesicle dynamics and GIPC function, offering a chemical tool to explore and modulate GIPC-related pathways in the context of altered intracellular trafficking. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632, a ROCK inhibitor, indirectly activates GIPC. By inhibiting ROCK-mediated GIPC phosphorylation, it modulates GIPC function in cellular processes. Y-27632's indirect activation of GIPC underscores the importance of GIPC phosphorylation in its activity, providing a pharmacological approach to investigate GIPC-related pathways and their potential impact on cellular functions regulated by GIPC. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene, a selective estrogen receptor modulator, indirectly activates GIPC. By interacting with estrogen receptors, it influences GIPC expression and function in estrogen-responsive tissues. Raloxifene's indirect activation of GIPC highlights the hormonal regulation of GIPC, providing a pharmacological tool to explore GIPC-related pathways in the context of hormonal signaling and potential implications in estrogen receptor-mediated cellular processes. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
DAPT, a gamma-secretase inhibitor, indirectly activates GIPC. By inhibiting Notch signaling, it influences GIPC-mediated cellular processes. DAPT's indirect activation of GIPC sheds light on the cross-talk between Notch signaling and GIPC function, providing a pharmacological tool to explore and modulate GIPC-related pathways in the context of altered Notch signaling dynamics. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA, a PKC activator, indirectly activates GIPC. By activating PKC, it influences GIPC-mediated signaling and cellular functions. TPA's indirect activation of GIPC reveals the role of PKC in regulating GIPC function, providing a pharmacological tool to explore and modulate GIPC-related pathways in the context of altered PKC signaling dynamics. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore, a dynamin inhibitor, indirectly activates GIPC. By inhibiting dynamin-mediated endocytosis, it influences GIPC-mediated cellular processes. Dynasore's indirect activation of GIPC reveals the connection between endocytic dynamics and GIPC function, offering a chemical tool to explore and modulate GIPC-related pathways in the context of altered endocytosis and its potential impact on GIPC-regulated cellular functions. | ||||||